Search research articles
Contact Us
Filters
Showing results (41-50 of 57) with videos related to
Page
of 6
Sort By:
Blood
|
October 21, 2016
Targeting BTK through microRNA in chronic lymphocytic leukemia
Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Jihong Xu, Pei-Jung Wu, Tzung-Huei Lai, et al.
Cancer Research
|
September 14, 2018
The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia
Federica Calore, Priya Londhe, Paolo Fadda, et al.
Blood
|
April 2, 2020
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
Fabienne Lucas, Karylin Larkin, C Thomas Gregory, et al.
Oncotarget
|
April 17, 2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia
Cecelia R Miller, Amy S Ruppert, Sydney Fobare, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2019
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Fabienne Lucas, Kerry A Rogers, Bonnie K Harrington, et al.
Science Advances
|
September 16, 2022
Targeting OXPHOS de novo purine synthesis as the nexus of <i>FLT3</i> inhibitor-mediated synergistic antileukemic actions
Pu Zhang, Lindsey T Brinton, Mehdi Gharghabi, et al.
Blood
|
April 16, 2010
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
Simona Rossi, Masayoshi Shimizu, Elisa Barbarotto, et al.
Leukemia
|
November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
Steven Sher, Ethan Whipp, Janek Walker, et al.
Cancer Discovery
|
August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D Reiff, Rose Mantel, Lisa L Smith, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 57) with videos related to
Sort By:
Page
of 6
Blood
|
October 21, 2016
Targeting BTK through microRNA in chronic lymphocytic leukemia
Arianna Bottoni, Lara Rizzotto, Tzung-Huei Lai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 10, 2022
Disruption of DNA Repair and Survival Pathways through Heat Shock Protein Inhibition by Onalespib to Sensitize Malignant Gliomas to Chemoradiation Therapy
Jihong Xu, Pei-Jung Wu, Tzung-Huei Lai, et al.
Cancer Research
|
September 14, 2018
The TLR7/8/9 Antagonist IMO-8503 Inhibits Cancer-Induced Cachexia
Federica Calore, Priya Londhe, Paolo Fadda, et al.
Blood
|
April 2, 2020
Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations
Fabienne Lucas, Karylin Larkin, C Thomas Gregory, et al.
Oncotarget
|
April 17, 2017
The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia
Cecelia R Miller, Amy S Ruppert, Sydney Fobare, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2019
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma
Fabienne Lucas, Kerry A Rogers, Bonnie K Harrington, et al.
Science Advances
|
September 16, 2022
Targeting OXPHOS de novo purine synthesis as the nexus of <i>FLT3</i> inhibitor-mediated synergistic antileukemic actions
Pu Zhang, Lindsey T Brinton, Mehdi Gharghabi, et al.
Blood
|
April 16, 2010
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
Simona Rossi, Masayoshi Shimizu, Elisa Barbarotto, et al.
Leukemia
|
November 14, 2022
VIP152 is a selective CDK9 inhibitor with pre-clinical in vitro and in vivo efficacy in chronic lymphocytic leukemia
Steven Sher, Ethan Whipp, Janek Walker, et al.
Cancer Discovery
|
August 11, 2018
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation
Sean D Reiff, Rose Mantel, Lisa L Smith, et al.
Page
of 6